{
    "clinical_study": {
        "@rank": "58716", 
        "arm_group": [
            {
                "arm_group_label": "Erigeron Injection", 
                "arm_group_type": "Experimental", 
                "description": "Erigeron Injection, 30ml,qd,i.v., for 7 days"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "normal saline, 500ml,i.v.,qd, for 7 days"
            }, 
            {
                "arm_group_label": "health volunteers", 
                "arm_group_type": "No Intervention", 
                "description": "health volunteers, no drug to be given."
            }
        ], 
        "brief_summary": {
            "textblock": "To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after\n      acute cerebral infarction,test is made by random double-blind controlled.patients with acute\n      cerebral infarction were divided randomly into erigeron injection+aspirin group,aspirin\n      group,and health people. The main indexes are the serum level of  VEGF, MMP-9 and EPC.The\n      review is made by the reference to NIHSS and so on. So, Erigeron Injection have the function\n      of promoting angiogenesis in multiple targets through this test."
        }, 
        "brief_title": "The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cerebral Infarction", 
        "condition_browse": {
            "mesh_term": [
                "Cerebral Infarction", 
                "Stroke", 
                "Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVE:\n\n      To study the effects of Erigeron Injection on human serum VEGF, MMP-9 and EPC levels after\n      acute cerebral infarction.\n\n      METHOD:\n\n      40 patients with acute cerebral infarction(in accordance with the inclusion criteria) were\n      divided randomly into erigeron injection+aspirin group,aspirin group,and 20 health people.\n      Erigeron injection+aspirin group and aspirin group drew peripheral blood on the prior\n      treatment,the posttreatment 1th, 3th and 7th day,and tested the level of  VEGF, MMP-9 and\n      EPC.Tested the health people one time."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  patients aged no younger than 18yrs\n\n          -  attack within 72 hours\n\n          -  NIHSS score in the 2-25 points\n\n          -  Ischemic Stroke occurred for the first time, or with a history of stroke disease but\n             without sequelae\n\n          -  Signed the informed consents\n\n        Exclusion Criteria:\n\n          -  patients aged younger than 18yrs\n\n          -  Patients with tumor, coronary heart disease, valvular heart disease, psoriasis,\n             rheumatism, hematologic diseases, infertility, varieties of acute inflammation\n\n          -  Patients with severe cognitive impairment\n\n          -  Refused to cooperate or been unable to cooperation for neurological disorders\n\n          -  Cerebral hemorrhage or hemorrhagic cerebral infarction\n\n          -  Unstable vital signs dued to massive cerebral infarction\n\n          -  Patients with serious heart, liver and renal insufficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01926834", 
            "org_study_id": "1201/01/006284"
        }, 
        "intervention": [
            {
                "arm_group_label": "Erigeron Injection", 
                "description": "Erigeron Injection, 30ml, iv, qd, for 7days", 
                "intervention_name": "Erigeron Injection", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "normal saline, 500ml,i.v.,qd, for 7 days", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "normal saline, 500ml,i.v.,qd, for 7 days"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "promoting angiogenesis in multiple targets", 
            "herbal medicine", 
            "traditional chinese medicine", 
            "random clinical trial"
        ], 
        "lastchanged_date": "August 19, 2013", 
        "number_of_arms": "3", 
        "official_title": "The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels", 
        "overall_contact": {
            "email": "jianwen_guo@msn.com", 
            "last_name": "Jianwen Guo, doctor", 
            "phone": "0086-13724899379"
        }, 
        "overall_contact_backup": {
            "email": "caiyefeng@126.com", 
            "last_name": "Yefeng Cai, master", 
            "phone": "(08620)81887233", 
            "phone_ext": "34530"
        }, 
        "overall_official": {
            "affiliation": "Guangdong Province Hospital of Tradtional Chinese Medicine", 
            "last_name": "Jianwen m Guo, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "China: State Administration of Traditional Chinese Medicine of the People's Republic of China", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "the serum level of VEGF,MMP-9 and EPC", 
            "safety_issue": "No", 
            "time_frame": "0-7days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01926834"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "National Institute of Health of stroke scale", 
            "safety_issue": "No", 
            "time_frame": "0-7days"
        }, 
        "source": "Guangzhou University of Traditional Chinese Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guangzhou University of Traditional Chinese Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}